Signal · Supply Chain & Logistics
Dr Lal PathLabs to acquire 70 pc stake in SN Genelab for Rs 168 crore
What the source reported
Source-reportedDr Lal PathLabs Ltd is set to acquire a 70% stake in SN Genelab for around Rs 168 crore, expanding its capabilities in genomics and diagnostic services. This move includes a potential earn-out of Rs 31.5 crore tied to performance. With the deal expected to close by November 30, 2026, SN Genelab will transition into a subsidiary of Dr Lal PathLabs.
- Publication
- The Economic Times - Industry · Trade Publication
- Published
- 24th September 2026
- Original report
- economictimes.indiatimes.com
ProcIntel stores what the source published in its feed — a headline, a summary and a link. It does not store or reproduce the full article.
What ProcIntel recorded
ProcIntel-derived- Category
- Supply Chain & Logistics
- Geography
- India
- Organisations
- None identified
- Collected
- 25th September 2026 · 02:31
Initial assessment ProcIntel's automatic, provisional read of this individual Signal -- Initial Significance and Initial Confidence, computed deterministically before any Event extraction or human review.
A provisional, automatically computed reading of this individual Signal, before Event extraction or human review. Not a final rating.
Initial Significance Low (16.0/100). Strongest contributor: Procurement Impact (6.0/30 points). Limiting factor: Geographic Breadth (0.0/10 points). Initial Confidence Low (32.5/100, data sufficiency: Partial). Strongest contributor: Source Authority (20.0/40 points). Limiting factor: Corroboration (2.5/25 points).
- Strongest contributor
- Procurement Impact
- Limiting factor
- Geographic Breadth